Kaare Meier

Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes: A Cohort Study of 259 Patients With Long-Term Follow-Up

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes : A Cohort Study of 259 Patients With Long-Term Follow-Up. / Poulsen, Dennis Møgeltoft; Sørensen, Jens Christian Hedemann; Blichfeldt-Eckhardt, Morten Rune; Gulisano, Helga Angela; Knudsen, Anne Lene Høst; Nikolajsen, Lone; Meier, Kaare.

I: Neuromodulation: Technology at the Neural Interface, Bind 24, Nr. 1, 01.2021, s. 76-85.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{a56d824911ed47468f34f3d2c93ba1f4,
title = "Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes: A Cohort Study of 259 Patients With Long-Term Follow-Up",
abstract = "OBJECTIVE: Spinal cord stimulation (SCS) is an important treatment modality used to treat chronic neuropathic pain. However, reported success rates of 26%-70% entail an increased focus on patient selection. An area of core interest is psychological evaluation, often using scales such as the Pain Catastrophizing Scale (PCS). The aim of this study was to assess the relation between baseline PCS scores obtained before implantation and SCS outcomes defined as (1) Rating on Patients' Global Impression of Change scale (PGIC), (2) Pain relief on the Numeric Rating Scale (NRS), (3) Cessation of pain medication, and (4) Risk of permanent explantation.MATERIALS AND METHODS: Using records from the Neurizon Neuromodulation Database, we performed a multicenter open cohort study of 259 permanently implanted SCS patients. Follow-up ranged from six months to nine years (median = three years). For each of the defined SCS outcomes, patients were grouped according to their latest follow-up registration. Subsequently, we used a one-way ANOVA and exact t-tests to compare mean baseline PCS scores between groups.RESULTS: No difference in mean baseline PCS scores was found between PGIC groups. Baseline PCS scores was not associated with the probability of obtaining 30% or 50% pain relief on latest registration. Baseline PCS scores of patients able to cease all usage of tricyclic antidepressants, antiepileptics, or opioids during SCS treatment did not differ from baseline scores of continuous users. We found no association between baseline PCS scores and risk of permanent explantation.CONCLUSION: This study did not demonstrate any associations between baseline PCS scores and SCS outcomes.",
author = "Poulsen, {Dennis M{\o}geltoft} and S{\o}rensen, {Jens Christian Hedemann} and Blichfeldt-Eckhardt, {Morten Rune} and Gulisano, {Helga Angela} and Knudsen, {Anne Lene H{\o}st} and Lone Nikolajsen and Kaare Meier",
note = "{\textcopyright} 2020 International Neuromodulation Society.",
year = "2021",
month = jan,
doi = "10.1111/ner.13213",
language = "English",
volume = "24",
pages = "76--85",
journal = "Neuromodulation: Technology at the Neural Interface",
issn = "1094-7159",
publisher = "Wiley-Blackwell Publishing, Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Pain Catastrophizing Does Not Predict Spinal Cord Stimulation Outcomes

T2 - A Cohort Study of 259 Patients With Long-Term Follow-Up

AU - Poulsen, Dennis Møgeltoft

AU - Sørensen, Jens Christian Hedemann

AU - Blichfeldt-Eckhardt, Morten Rune

AU - Gulisano, Helga Angela

AU - Knudsen, Anne Lene Høst

AU - Nikolajsen, Lone

AU - Meier, Kaare

N1 - © 2020 International Neuromodulation Society.

PY - 2021/1

Y1 - 2021/1

N2 - OBJECTIVE: Spinal cord stimulation (SCS) is an important treatment modality used to treat chronic neuropathic pain. However, reported success rates of 26%-70% entail an increased focus on patient selection. An area of core interest is psychological evaluation, often using scales such as the Pain Catastrophizing Scale (PCS). The aim of this study was to assess the relation between baseline PCS scores obtained before implantation and SCS outcomes defined as (1) Rating on Patients' Global Impression of Change scale (PGIC), (2) Pain relief on the Numeric Rating Scale (NRS), (3) Cessation of pain medication, and (4) Risk of permanent explantation.MATERIALS AND METHODS: Using records from the Neurizon Neuromodulation Database, we performed a multicenter open cohort study of 259 permanently implanted SCS patients. Follow-up ranged from six months to nine years (median = three years). For each of the defined SCS outcomes, patients were grouped according to their latest follow-up registration. Subsequently, we used a one-way ANOVA and exact t-tests to compare mean baseline PCS scores between groups.RESULTS: No difference in mean baseline PCS scores was found between PGIC groups. Baseline PCS scores was not associated with the probability of obtaining 30% or 50% pain relief on latest registration. Baseline PCS scores of patients able to cease all usage of tricyclic antidepressants, antiepileptics, or opioids during SCS treatment did not differ from baseline scores of continuous users. We found no association between baseline PCS scores and risk of permanent explantation.CONCLUSION: This study did not demonstrate any associations between baseline PCS scores and SCS outcomes.

AB - OBJECTIVE: Spinal cord stimulation (SCS) is an important treatment modality used to treat chronic neuropathic pain. However, reported success rates of 26%-70% entail an increased focus on patient selection. An area of core interest is psychological evaluation, often using scales such as the Pain Catastrophizing Scale (PCS). The aim of this study was to assess the relation between baseline PCS scores obtained before implantation and SCS outcomes defined as (1) Rating on Patients' Global Impression of Change scale (PGIC), (2) Pain relief on the Numeric Rating Scale (NRS), (3) Cessation of pain medication, and (4) Risk of permanent explantation.MATERIALS AND METHODS: Using records from the Neurizon Neuromodulation Database, we performed a multicenter open cohort study of 259 permanently implanted SCS patients. Follow-up ranged from six months to nine years (median = three years). For each of the defined SCS outcomes, patients were grouped according to their latest follow-up registration. Subsequently, we used a one-way ANOVA and exact t-tests to compare mean baseline PCS scores between groups.RESULTS: No difference in mean baseline PCS scores was found between PGIC groups. Baseline PCS scores was not associated with the probability of obtaining 30% or 50% pain relief on latest registration. Baseline PCS scores of patients able to cease all usage of tricyclic antidepressants, antiepileptics, or opioids during SCS treatment did not differ from baseline scores of continuous users. We found no association between baseline PCS scores and risk of permanent explantation.CONCLUSION: This study did not demonstrate any associations between baseline PCS scores and SCS outcomes.

U2 - 10.1111/ner.13213

DO - 10.1111/ner.13213

M3 - Journal article

C2 - 32929834

VL - 24

SP - 76

EP - 85

JO - Neuromodulation: Technology at the Neural Interface

JF - Neuromodulation: Technology at the Neural Interface

SN - 1094-7159

IS - 1

ER -